Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Price controls seen as key to Europe's drug innovation lag

Nature Reviews Drug Discovery volume 6, pages 257–258 (2007)Cite this article

Pharmaceutical innovation is not only occurring faster in the United States than in Europe, but the gap is getting wider.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The EMEA meets its performance goals, but lags the FDA in new drug approvals.

Author information

Authors and Affiliations

  1. London, UK

    Peter Mitchell

Authors
  1. Peter Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mitchell, P. Price controls seen as key to Europe's drug innovation lag. Nat Rev Drug Discov 6, 257–258 (2007). https://doi.org/10.1038/nrd2293

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2293

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing